Bristol-Myers Wins Patent Fight Over Generic HIV Drug

Law360, Los Angeles (November 5, 2013, 9:11 PM EST) -- A Delaware federal judge on Tuesday handed victory to Bristol-Myers Squibb Co. in its battle to assert its patent on its HIV treatment Sustiva against generic drugmakers Mylan Pharmaceuticals Inc. and Matrix Laboratories Ltd., finding a generic version of the drug would infringe the patent.

Bristol-Myers, which markets and sells Sustiva in 600-milligram efavirenz tablets, filed the suit in August 2010 after the generic-drug makers filed an abbreviated new drug application asking for approval to make and sell a generic version of Sustiva for HIV type...
To view the full article, register now.